WO2000032178A2 - Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments - Google Patents
Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments Download PDFInfo
- Publication number
- WO2000032178A2 WO2000032178A2 PCT/US1999/028362 US9928362W WO0032178A2 WO 2000032178 A2 WO2000032178 A2 WO 2000032178A2 US 9928362 W US9928362 W US 9928362W WO 0032178 A2 WO0032178 A2 WO 0032178A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- disorders
- sibutramine
- symptoms
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the present invention relates to the pharmacological treatment of various secondary neurological, behavioral and cognitive symptoms or disorders emanating out of brain or systemic impairments, i.e, primary impairments.
- the secondary symptoms and disorders include as non-limiting examples, tic and behavioral disorders including Tourette's syndrome and severe non-Tourette's motor or vocal tics; Posttraumatic Stress Disorder (PTSD); atypical attention deficit disorder with or without hyperactivity; frontal lobe defects of executive function; oscillopsia; self-mutilation; violence or rage such as in intermittent explosive disorder; asocial behavior; sexual disorders (including gender choice difficulties or hyposexuality); psychological (psychosis, violence, and confusion) and motor symptoms of Huntington's Disease (Huntington's Chorea); fatigue, exhaustion, sleep problems, and pain of Chronic Fatigue Syndrome with or without Fibromyalgia; psychosis with multiple hallucinations and delusions secondary to brain injury; and opiate narcotic addiction.
- a symptom is a single manifestation while a disorder involves more than one symptom or a cluster of symptoms.
- the symptoms and disorders are secondary to the primary impairments and emanate from neurological diseases or brain lesions including Tourette's Disease, non-Tourette's tic disorders, Asperger's Syndrome, temporal lobe or other focal epilepsy. Huntington's Disease, brain tumors or cysts, systemic lupus erythematosus, viral infections and their resulting neurological injuries, and various psychological disorders such as multiple personality disorder, borderline personality, organic psychosis, and severe traumatic experiences. BACKGROUND OF THE INVENTION
- Gilles De La Tourette's syndrome is characterized by motor and vocal tics, i.e., involuntary, sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization.
- Pharmacologic therapy has included low doses of dopamine-2 blockers and dopamine-antagonists including haloperidol, risperidone, or pimozide. T.M.
- Violence or rage can also be categorized as an impulse control disorder. There is a loss of control grossly out of proportion to any precipitating psychosocial stresses. Disabling outbursts of rage and violent behavior can be related to chronic brain syndrome associated with irreversible CNS (central nervous system) lesions. Yudofsky et al., Am. J. Psychiatry 138:218-220, 1981. Disorders characterized by severe episodic dyscontrol can result from brain dysfunction, e.g., resulting from a failure of modulation of electrical disturbances in the limbic system (amygdala, hippocampus, hypothalamus), temporal lobe epilepsy (TLE), brain lesions or injuries which can have neurological side effects.
- amygdala, hippocampus, hypothalamus central nervous system
- TLE temporal lobe epilepsy
- Temporal lobe epilepsy and other organic brain disorders may be associated with various sexual impairments. See, e.g., D.M.Bear, "Temporal Lobe
- FM is differentiated from CFS by specific point pain spots in the muscles and CFS differs from FM by having a sore throat, tender cervical or axillary lymph nodes, variably elevated erythrocyte sedimentation rate, occasional low grade temperature, and a variety of immunologic or neuroendocrinologic test values (none of which are consistent or indicative of any known etiologic agent) See, e.g., K. Fukuda et al.. Ann. Intern. Med. 121 :953-959, 1994; A. L. Komaroff et al., Rev. Infect. Dis. 13(Suppl. 1):S8-11, 1991. Both are clearly different from a depressive diagnosis. A recent study by A. L. Komaroff et al, Am. J. Med. 101 :281-
- sibutramine activates endo ⁇ hins or, at the very least, modifies the endo ⁇ hinergic opioid systems to promote serenity and lack of pain and stress, and to reduce craving for heroin.
- Treatment had included phenytoin, phenobarbital, clonidine, carbamazepine, fenfluramine, magnesium penoline, valproic acid, hydroxyzine, methylphenidate, bromocriptine, clomipramine, desipramine, selegiline, propranolol, clozapine, felbamate, tacrine, gabapentin, risperidone, lamotrigine, olanzapine, donepezil, and quetiapine without any good results.
- the patient was started on sibutramine 10 mg in the morning and was seen two days after a very severe thunderstorm with the threat of tornadoes. The patient reported she stayed up four hours of that night watching for tornadoes, completely oblivious of her former psychotic fear of thunder.
- Intracerebral Porencephalic Cyst With Oscillopsia (Problem No. 5) Sibutramine Patient No. 111 A 58-year-old man suffered a severe head injury in 1976 with a fractured skull, coma, and an intracerebral (porencephalic) cyst caused by the traumatic blockage of his cerebral spinal fluid in his brain. This cyst was repaired surgically with a brain ventricular - jugular vein shunt. This had permitted him to work continuously with concomitant treatment with carbamazepine, valproic acid, and dextroamphetamine until early 1998 when he began to suffer severe attacks of seeminglyly altered vision, dizziness, ataxia, and confusion.
- a 46-year-old married woman with a lifelong history of ADHD was treated for four years with multiple medications including methylphenidate, magnesium pemoline, dextroamphetamine, and long-acting amphetamine salts without success and negative side effects.
- the amphetamines made her nervous, jittery, and unable to sleep.
- the methylphenidate and magnesium pemoline on the other hand, made her sleepy.
- These medications did not calm her hyperactivity without sedating her. She was started on sibutramine 10 mg every morning by mouth. Immediately she noted a calming and an alerting effect not seen with the dopamine agonist analeptics. After the first month, her dose was changed to 5 mg three times daily due to a five hour duration of effects. She has continued on the medication to date (over six months) as did her daughter who also failed to respond to all of the various analeptic dopaminergic drugs used for ADHD.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69931957T DE69931957T2 (en) | 1998-12-02 | 1999-12-01 | USE OF SIBUTRAMINE FOR THE TREATMENT OF CNS DISORDERS CAUSED BY ORGANIC DISORDER |
AU17488/00A AU764049B2 (en) | 1998-12-02 | 1999-12-01 | Treatment of disorders secondary to organic impairments |
EP99960633A EP1135115B1 (en) | 1998-12-02 | 1999-12-01 | Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
CA002353133A CA2353133C (en) | 1998-12-02 | 1999-12-01 | Treatment of disorders secondary to organic impairments |
JP2000584874A JP2003504303A (en) | 1998-12-02 | 1999-12-01 | Treatment of disorders derived from organic disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/204,124 US6323242B1 (en) | 1998-12-02 | 1998-12-02 | Treatment of disorders secondary to organic impairments |
US09/204,124 | 1998-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000032178A2 true WO2000032178A2 (en) | 2000-06-08 |
WO2000032178A3 WO2000032178A3 (en) | 2000-10-05 |
Family
ID=22756736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/028362 WO2000032178A2 (en) | 1998-12-02 | 1999-12-01 | Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments |
Country Status (8)
Country | Link |
---|---|
US (2) | US6323242B1 (en) |
EP (1) | EP1135115B1 (en) |
JP (1) | JP2003504303A (en) |
AT (1) | ATE329588T1 (en) |
AU (1) | AU764049B2 (en) |
CA (1) | CA2353133C (en) |
DE (1) | DE69931957T2 (en) |
WO (1) | WO2000032178A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003039598A1 (en) * | 2001-11-05 | 2003-05-15 | Cypress Bioscience, Inc. | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain |
EP1320360A1 (en) * | 2000-09-14 | 2003-06-25 | Sepracor Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
EP1404308A1 (en) * | 2001-04-17 | 2004-04-07 | Snowden Pharmaceuticals, LLC | Treatment of disorders secondary to organic impairments |
EP1499309A1 (en) * | 2002-04-24 | 2005-01-26 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
JP2005531594A (en) | 2002-05-30 | 2005-10-20 | ニューロサーチ、アクティーゼルスカブ | Triple monoamine reuptake inhibitors for the treatment of chronic pain |
US6992110B2 (en) | 2001-11-05 | 2006-01-31 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
WO2008042773A2 (en) * | 2006-09-29 | 2008-04-10 | Pdxrx, Inc. | Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders |
US7989500B2 (en) | 2006-09-15 | 2011-08-02 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
WO2013102195A1 (en) | 2011-12-30 | 2013-07-04 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552087B1 (en) * | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
US6803387B1 (en) * | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
CA2438816A1 (en) * | 2001-02-22 | 2002-09-06 | Classen Immunotherapies, Inc. | Improved algorithms and methods for products safety |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
AU2002347984A1 (en) * | 2001-11-30 | 2003-06-17 | Eli Lilly And Company | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
US20030195186A1 (en) * | 2002-04-10 | 2003-10-16 | University Of Florida | Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction |
US20070032554A1 (en) * | 2003-08-27 | 2007-02-08 | Elililly And Company A Corporation | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors |
US20080269306A1 (en) * | 2004-12-27 | 2008-10-30 | Alpha 2 Pharmaceutica Ab | Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor |
WO2007034910A1 (en) * | 2005-09-22 | 2007-03-29 | Eisai R & D Management Co., Ltd. | Medicinal composition for treating bulimia and depression accompanying bulimia |
SI1937276T1 (en) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Improved testosterone gel and method of use |
US20110046120A1 (en) * | 2006-10-26 | 2011-02-24 | Mclean Hospital Corporation | Treatment of impulse control disorders |
US11033554B2 (en) * | 2015-07-24 | 2021-06-15 | United States Government As Represented By The Department Of Veterans Affairs | Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
US11596622B2 (en) | 2017-09-07 | 2023-03-07 | Nls Pharmaceutics Ag | Mazindol treatment for heroin dependence and substance use disorder |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0339280A2 (en) * | 1988-03-31 | 1989-11-02 | The Boots Company PLC | Use of N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine for treatment of cerebral disorders |
WO1994000114A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
WO1994000047A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
WO1995021615A1 (en) * | 1994-02-11 | 1995-08-17 | Knoll Ag | Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders |
WO2000010551A2 (en) * | 1998-08-24 | 2000-03-02 | Sepracor Inc. | Methods of using and compositions comprising dopamine reuptake inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443449A (en) | 1981-04-06 | 1984-04-17 | The Boots Company Limited | Arylcyclobutylalkylamines and anti-depression composition and methods using same |
ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
GB8704777D0 (en) | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5780051A (en) | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
US5459164A (en) | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
US5663178A (en) | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
GB9619961D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
US5795880A (en) | 1996-12-30 | 1998-08-18 | Louisiana State University Medical Center Foundation | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
US5804596A (en) | 1997-02-27 | 1998-09-08 | Sabinsa Corporation | Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders |
US5922341A (en) | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
US6075028A (en) | 1999-09-23 | 2000-06-13 | Graham; Richard | Method of treating Tourette's syndrome and related CNS disorders |
-
1998
- 1998-12-02 US US09/204,124 patent/US6323242B1/en not_active Expired - Lifetime
-
1999
- 1999-12-01 WO PCT/US1999/028362 patent/WO2000032178A2/en active IP Right Grant
- 1999-12-01 EP EP99960633A patent/EP1135115B1/en not_active Expired - Lifetime
- 1999-12-01 JP JP2000584874A patent/JP2003504303A/en active Pending
- 1999-12-01 DE DE69931957T patent/DE69931957T2/en not_active Expired - Lifetime
- 1999-12-01 AU AU17488/00A patent/AU764049B2/en not_active Ceased
- 1999-12-01 CA CA002353133A patent/CA2353133C/en not_active Expired - Fee Related
- 1999-12-01 AT AT99960633T patent/ATE329588T1/en not_active IP Right Cessation
-
2001
- 2001-04-17 US US09/836,156 patent/US20030207943A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0339280A2 (en) * | 1988-03-31 | 1989-11-02 | The Boots Company PLC | Use of N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine for treatment of cerebral disorders |
WO1994000114A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
WO1994000047A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
WO1995021615A1 (en) * | 1994-02-11 | 1995-08-17 | Knoll Ag | Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders |
WO2000010551A2 (en) * | 1998-08-24 | 2000-03-02 | Sepracor Inc. | Methods of using and compositions comprising dopamine reuptake inhibitors |
Non-Patent Citations (1)
Title |
---|
A.M. GRAY: "The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds" BR. J. PHARMACOL., vol. 124, no. 4, June 1998 (1998-06), pages 69-674, XP000909217 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1320360A1 (en) * | 2000-09-14 | 2003-06-25 | Sepracor Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
JP2004529850A (en) * | 2000-09-14 | 2004-09-30 | セプラコア インコーポレーテッド | Methods and compositions for the treatment and prevention of sexual dysfunction |
EP1404308A1 (en) * | 2001-04-17 | 2004-04-07 | Snowden Pharmaceuticals, LLC | Treatment of disorders secondary to organic impairments |
EP1404308A4 (en) * | 2001-04-17 | 2007-05-02 | Snowden Pharmaceuticals Llc | Treatment of disorders secondary to organic impairments |
WO2003039598A1 (en) * | 2001-11-05 | 2003-05-15 | Cypress Bioscience, Inc. | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain |
US6992110B2 (en) | 2001-11-05 | 2006-01-31 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
EP2322225A1 (en) * | 2001-11-05 | 2011-05-18 | Cypress Bioscience, Inc. | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
US7820643B2 (en) * | 2001-11-05 | 2010-10-26 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
JP2010070573A (en) * | 2002-04-24 | 2010-04-02 | Cypress Bioscience Inc | Prevention and treatment of functional somatic disorder including stress-related disorder |
EP1499309A1 (en) * | 2002-04-24 | 2005-01-26 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
JP2005523334A (en) * | 2002-04-24 | 2005-08-04 | サイプレス バイオサイエンス, インコーポレイテッド | Prevention and treatment of functional disabilities, including stress related disorders |
EP1499309A4 (en) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | Prevention and treatment of functional somatic disorders, including stress-related disorders |
JP2005531594A (en) | 2002-05-30 | 2005-10-20 | ニューロサーチ、アクティーゼルスカブ | Triple monoamine reuptake inhibitors for the treatment of chronic pain |
US7989500B2 (en) | 2006-09-15 | 2011-08-02 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
US8338632B2 (en) | 2006-09-15 | 2012-12-25 | Reviva Pharmaceuticals, Inc. | Cycloalkylmethylamines |
US8372883B2 (en) | 2006-09-15 | 2013-02-12 | Reviva Pharmaceuticals, Inc. | Methods of using cycloalkylmethylamines |
US8445714B2 (en) | 2006-09-15 | 2013-05-21 | Reviva Pharmaceuticals, Inc. | Cycloalkylmethylamines |
US9296681B2 (en) | 2006-09-15 | 2016-03-29 | Reviva Pharmaceuticals, Inc. | Cycloalkylmethylamines |
US9302981B2 (en) | 2006-09-15 | 2016-04-05 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
WO2008042773A3 (en) * | 2006-09-29 | 2008-08-28 | Pdxrx Inc | Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders |
WO2008042773A2 (en) * | 2006-09-29 | 2008-04-10 | Pdxrx, Inc. | Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
US9096515B2 (en) | 2010-07-02 | 2015-08-04 | Reviva Pharmaceuticals, Inc. | Methods of using cycloalkylmethylamine derivatives |
WO2013102195A1 (en) | 2011-12-30 | 2013-07-04 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
Also Published As
Publication number | Publication date |
---|---|
EP1135115B1 (en) | 2006-06-14 |
JP2003504303A (en) | 2003-02-04 |
US20030207943A1 (en) | 2003-11-06 |
AU1748800A (en) | 2000-06-19 |
CA2353133A1 (en) | 2000-06-08 |
AU764049B2 (en) | 2003-08-07 |
US6323242B1 (en) | 2001-11-27 |
DE69931957D1 (en) | 2006-07-27 |
CA2353133C (en) | 2009-11-03 |
DE69931957T2 (en) | 2007-01-25 |
ATE329588T1 (en) | 2006-07-15 |
WO2000032178A3 (en) | 2000-10-05 |
EP1135115A2 (en) | 2001-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6323242B1 (en) | Treatment of disorders secondary to organic impairments | |
Billiard et al. | EFNS guidelines on management of narcolepsy | |
Rickels et al. | Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone | |
US6057373A (en) | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists | |
Mead et al. | Mephedrone and MDMA: a comparative review | |
US6696495B2 (en) | Treatment of disorders secondary to organic impairments | |
Thorpy | Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management | |
AU2002258820A1 (en) | Treatment of disorders secondary to organic impairments | |
US20100298305A1 (en) | Tizanidine for the treatment of post-traumatic stress disorder and nightmares | |
Billiard et al. | Narcolepsy | |
Rizwan et al. | Efficacy of behavioural intervention, antipsychotics, and alpha agonists in the treatment of tics disorder in Tourette’s syndrome | |
WO1999063997A1 (en) | Use of clonidine for treatment of addictions, epilepsy, sleep disorders, eating disorders and migraines | |
US5102913A (en) | Treatment for cocaine use employing valproic acid | |
Walker | Neurotic, stress-related and somatoform disorders | |
O’Brien et al. | Psychopharmacological treatments for substance use disorders | |
la Casa-Fages et al. | Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson's disease | |
Berger et al. | Mental health: progress and problems | |
Cosgrove | Fluvoxamine in the treatment of depressive illness in children and adolescents | |
Dose | Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes | |
Wesson et al. | A clinical approach to diagnosis and treatment of amphetamine abuse | |
Akbar et al. | A Case Report: Is There a Drug-Induced Gambling Disorder? | |
Shinde et al. | MECHANISM AND CLASSIFICATION OF ANTIDEPRESSANT DRUG: A REVIEW | |
Masri et al. | Treating Narcolepsy and Idiopathic Hypersomnia | |
CHIODO et al. | MEDICATION STRATEGIES FOR THE TREATMENT OF COCAINE DEPENDENCE | |
Toms III | Sigma-1 receptors: potential therapeutic targets for substance use disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17488 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2353133 Country of ref document: CA Ref country code: CA Ref document number: 2353133 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17488/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 584874 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999960633 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999960633 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 17488/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999960633 Country of ref document: EP |